Drugs / LM-061
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04737122 | May 2021 → Jul 2022 | metastatic neoplasm | LaNova Medicines Limited | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04882176 | May 2021 → Feb 2023 | — | LaNova Medicines Limited | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LM-061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04882176 ↗ |
| Route | Oral | “multiple oral doses of LM-061 once daily” NCT04737122 ↗ |